中國銀行(601988.SH):減記型無固定期限資本債券發行完畢
格隆匯7月24日丨中國銀行(601988.SH)公佈,公司於2023年6月30日召開的股東大會審議批準了本行發行不超過4,500億元人民幣或等值外幣資本工具的議案。經相關監管機構批準,本行於2025年7月22日在全國銀行間債券市場發行減記型無固定期限資本債券(簡稱“本期債券”),並於2025年7月24日發行完畢。
本期債券發行規模爲300億元人民幣,前5年票面利率爲1.97%,每5年調整一次,在第5年及之後的每個付息日附發行人贖回權。
本期債券募集的資金將依據適用法律和監管部門的批準,補充本行的其他一級資本。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.